The feasibility of this route of administration has been demonstrated for delivery of drugs like paclitaxel, doxorubicin and curcumin in pre-clinical models with chemically induced carcinomas and in transgenic HER-2/neu models, resulting in regression of established tumors and prevention of tumor development (Murata et al., 2006; Chun et al., 2012; Krause et al., 2013). This evidence concerns the gene ERBB2 and neoplasm.